🇺🇸 영어 원문
Alzheimer’s disease is the leading cause of dementia and currently affects more than seven million people in the United States. Some available treatments can slow the disease, but most primarily address symptoms, and none can cure it.
“Alzheimer’s is a condition that remains recalcitrant to the scientific community’s attempts at developing a cure or preventative treatment,” said Daniel Schultz, a former postdoctoral fellow in the Vanderbilt University Warren Center for Neuroscience Drug Discovery.
One major obstacle to developing better therapies is that researchers still do not fully understand the biology behind Alzheimer’s disease. The same problem affects research into many other neurological diseases and neurodevelopmental disorders.
Scientists have identified genes and proteins that may contribute to these conditions, but studying them can be extremely difficult when researchers lack a reliable way to change how those biological targets behave.
One approach involves using tool compounds. These chemicals interact with particular proteins and either raise or reduce their activity. Although many tool compounds are unsuitable for use as medicines because they may affect unintended targets or cause toxicity, they are still highly valuable for investigating what a protein does. That knowledge can become an important early step toward developing new treatments.
In a study published in ACS Chemical Neuroscience, Schultz and co-first author Lauren Parr, a Ph.D. student in the Department of Pharmacology, developed a compound that selectively inhibits TAOK-1. The protein has been linked to Alzheimer’s disease, but it has remained poorly understood partly because researchers have lacked suitable compounds for studying it.
Most of the work was carried out at the WCNDD under the leadership of Executive Director Craig Lindsley. The WCNDD is a clinical-stage biotech start-up within Vanderbilt. Its drug discovery pipeline currently includes five compounds in phase I clinical trials.
The center is also a founding pillar of the new Vanderbilt Institute for Therapeutic Advances, a next-generation drug discovery institute that is also led by Lindsley.
To find useful compounds, Schultz, Parr, and other WCNDD researchers created a large collection of related molecules. Each one had a slightly different structure. The team then evaluated how the compounds affected TAOK-1 and assessed whether they had properties considered desirable in potential drugs.
“This project showcased the strength of the WCNDD’s drug discovery infrastructure,” Schultz said.
The collaboration led to the discovery of VU6083859, the first selective inhibitor of TAOK-1. The compound could provide a starting point for research aimed at developing future Alzheimer’s disease treatments.
Another molecule produced an unexpected result. The compound, named VU6080195, activated all three proteins in the TAOK family rather than inhibiting them.
“Our understanding of TAOK proteins largely centers around their inhibition, so we are excited at the prospect of studying the neurological effects of increasing their activity,” Schultz said. “As scientists, we can get lost in planning our projects to the last detail and expecting things to go a certain way, so it was quite fun to see this unexpected result.”
Schultz hopes the two compounds will encourage more researchers to investigate the TAOK protein family. So far, these proteins have received relatively little attention.
🇰🇷 한국어 요약
알츠하이머병은 치매의 가장 큰 원인이며, 미국에서만 700 만 명 이상이 앓고 있습니다. 하지만 아직 완치제는 없습니다. 과학자들은 알츠하이머의 정확한 원인을 완전히 이해하지 못해 치료제 개발에 어려움을 겪고 있습니다. 이번 연구에서는 알츠하이머와 관련된 ‘TAOK-1’이라는 단백질을 연구하기 위해 새로운 화학 물질을 개발했습니다. 이 물질은 단백질을 억제하거나 활성화하는 역할을 합니다. 연구 결과, TAOK-1 을 억제하는 물질과 오히려 활성화하는 물질을 발견했는데, 이는 기존에 생각하지 못했던 새로운 연구 방향을 제시합니다. 과학자들은 이러한 발견이 알츠하이머 치료제 개발의 중요한 첫걸음이 되기를 기대합니다.
🔑 핵심 단어 (Vocabulary)
- recalcitrant – (의견이나 명령을) 따르지 않는, 완고한 – Alzheimer’s is a condition that remains recalcitrant to the scientific community’s attempts…
- inhibit – 억제하다, 방해하다 – …developed a compound that selectively inhibits TAOK-1.
- compound – 화합물, 성분 – Two new compounds could reveal hidden drivers…
- neurological – 신경학적인 – The same problem affects research into many other neurological diseases…
- toxicity – 독성 – …unsuitable for use as medicines because they may affect unintended targets or cause toxicity…
- infrastructure – 기반 시설, 인프라 – This project showcased the strength of the WCNDD’s drug discovery infrastructure…
- collaboration – 협력, 협업 – The collaboration led to the discovery of VU6083859…
- unexpected – 예상치 못한 – Another molecule produced an unexpected result.
- prospect – 전망, 가능성 – …we are excited at the prospect of studying the neurological effects…
- pipeline – (연구나 사업의) 진행 과정, 파이프라인 – Its drug discovery pipeline currently includes five compounds…
🔗 원문 링크
https://www.sciencedaily.com/releases/2026/08/260802223437.htm